Features, management and prognosis of Chilean patients with non valvular atrial fibrillation: GARFIELD AF registry

dc.contributor.authorCorbalan, Ramon
dc.contributor.authorConejeros, Carlos
dc.contributor.authorRey, Carlos
dc.contributor.authorStockins, Benjamin
dc.contributor.authorEgers, German
dc.contributor.authorAstudillo, Carlos
dc.contributor.authorLanas, Fernando
dc.contributor.authorPotthoff, Sergio
dc.contributor.authorHouzvic, Cesar
dc.contributor.authorMontecinos, Humberto
dc.contributor.authorCharme, Gustavo
dc.contributor.authorBugueno, Claudio
dc.contributor.authorAguilar, Juan
dc.contributor.authorAriagada, German
dc.contributor.authorMarin, Patricio
dc.contributor.authorLarico, Martin
dc.contributor.authorRepresentacion Grp GARFIELD AF
dc.date.accessioned2024-01-10T12:05:28Z
dc.date.available2024-01-10T12:05:28Z
dc.date.issued2017
dc.description.abstractBackground: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with high rates of death, ischemic stroke and systemic embolism (SE). There is scarce information about clinical characteristics and use of antithrombotic therapies in Chilean patients with non-valvular AF. Aim: To describe the characteristics and 1-year outcomes of patients with recently diagnosed AF recruited in Chile into the prospective global GARFIELD-AF registry. Material and Methods: Between 2011-2016, we prospectively registered information of 971 patients recruited at 15 centers, 85% of them from the public system and 15% from the private sector. Demographics, clinical characteristics and use of antithrombotic therapies were recorded for all patients. Adverse clinical outcomes were analyzed in 711 patients with 1-year follow-up. Results: The mean age was 71.5 years (66-79), 50% were men. Mean CHAD2S2 Vasc and HAS BLED scores for stroke risk were 3.3 (2.0-4.0) and 1.5 (1.0-2.0) respectively. Oral anticoagulants were prescribed in 82% of patients. Seventy percent received Vitamin K antagonists, 10% novel direct anticoagulants or antiplatelet therapy and only 8% did not receive any antithrombotic therapy. Mean time in optimal therapeutic range (an international normalized ratio of 2 to 3), was achieved in only 40.7% (23.0-54.8) of patients receiving Vitamin K antagonists. One year rates of death, stroke/systemic embolism and bleeding were 4.75 (3.36-6.71), 2.40 (1.47-3.92) and 1.64% (0.91-2.97) per 100 person-years. Ischemic stroke occurred in 1.8% and hemorrhagic stroke in 0.8% of patients at 1-year of follow up. Conclusions: Although the use of vitamin K antagonists at baseline was high, the mean time in optimal therapeutic range was low. Mortality and stroke rates are higher than those reported in other contemporary registries.
dc.format.extent9 páginas
dc.fuente.origenWOS
dc.identifier.eissn0717-6163
dc.identifier.issn0034-9887
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/76015
dc.identifier.wosidWOS:000413293700001
dc.information.autorucMedicina;Corbalan R;S/I;98700
dc.issue.numero8
dc.language.isoes
dc.nota.accesoSin adjunto
dc.pagina.final971
dc.pagina.inicio963
dc.publisherSOC MEDICA SANTIAGO
dc.revistaREVISTA MEDICA DE CHILE
dc.rightsregistro bibliográfico
dc.subjectAnticoagulants
dc.subjectAtrial Fibrillation
dc.subjectChile
dc.subjectPrognosis
dc.subjectCOUNTRIES
dc.subjectSTROKE
dc.subjectRISK
dc.subjectANTICOAGULATION
dc.subjectMORTALITY
dc.subjectWARFARIN
dc.subjectOUTCOMES
dc.subjectTHERAPY
dc.subjectDISEASE
dc.subjectCARE
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleFeatures, management and prognosis of Chilean patients with non valvular atrial fibrillation: GARFIELD AF registry
dc.typeartículo
dc.volumen145
sipa.codpersvinculados98700
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Features, management and prognosis of Chilean patients with non valvular atrial fibrillation; GARFIELD AF registry.pdf
Size:
659.29 KB
Format:
Adobe Portable Document Format
Description: